| US 7,476,402 B2 | ||
| Methods and compositions for deterring abuse of opioid containing dosage forms | ||
| Vijai Kumar, Morris Plains, N.J. (US); David Dixon, Woodside, N.Y. (US); Divya Tewari, Suffern, N.Y. (US); and Dilip B. Wadgaonkar, Suffern, N.Y. (US) | ||
| Assigned to Acura Pharmaceuticals, Inc., Palatine, Ill. (US) | ||
| Filed on Feb. 27, 2007, as Appl. No. 11/657,360. | ||
| Application 11/657360 is a continuation of application No. 10/723654, filed on Nov. 26, 2003, granted, now 7,201,920. | ||
| Prior Publication US 2007/0264327 A1, Nov. 15, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/135 (2006.01); A61K 31/485 (2006.01); A61K 31/4468 (2006.01); A01N 43/647 (2006.01); A01N 43/40 (2006.01); A01N 43/46 (2006.01) | ||
| U.S. Cl. 424—452 [514/282; 514/242; 514/333; 514/277; 514/214.03; 514/740; 514/747; 514/764] | 18 Claims |
| 1. A therapeutic pharmaceutical composition comprising a mixture including:
(a) at least one opioid analgesic agonistic to the mu-receptor selected from the group consisting of: alfentanil, buprenorphine,
carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, fentanyl, hydrocodone, hydromorphone, β-hydroxy-3-methylfentanyl,
levo-α-acetylmethadol, lofentanil, methadone, morphine, oxycodone, oxymorphone, propoxyphene, remifentanil, sufentanil, tilidine,
and tramadol;
(b) at least one opioid analgesic agonistic to the kappa-receptor selected from the group consisting of: butorphanol, diprenorphine,
etorphine, levorphanol, meperidine, nalbuphine, pentazocine, and pethidine;
(c) gel-forming polyethylene oxide at about 3 to about 40 percent by weight;
(d) at least one disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting
of crospovidone, sodium starch glycolate, and croscarmellose sodium; and
(e) sodium lauryl sulfate at about 1 to 10 percent by weight.
|